S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Key facts

Sponsor

SWOG Cancer Research Network

Principal Investigator

Edgar Ben-Josef, MD

Barbara Ann Karmanos Cancer Institute

Intervention

capecitabine(drug)

Enrollment

105 enrolled

Eligibility

18-120 years · All sexes

Timeline

2008 – 2017

Study locations (30)

• Regional Medical Center, Anniston, Alabama, United States
• Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States
• Peninsula Medical Center, Burlingame, California, United States
• Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
• Kaiser Permanente Medical Center - Los Angeles, Los Angeles, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
• Sutter Health - Western Division Cancer Research Group, Novato, California, United States
• Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California, United States
• California Pacific Medical Center - California Campus, San Francisco, California, United States
• Sutter Pacific Medical Foundation, Santa Rosa, California, United States
• Sutter Solano Medical Center, Vallejo, California, United States
• Aurora Presbyterian Hospital, Aurora, Colorado, United States
• University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States
• Boulder Community Hospital, Boulder, Colorado, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Carcinoma of gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT06901622
  Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
  The First Affiliated Hospital of Zhengzhou University
• RECRUITINGNCT07337850
  Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
  Tata Memorial Centre
• RECRUITINGPHASE2NCT06440993
  Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• ACTIVE NOT RECRUITINGPHASE2NCT05712356
  A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
  Lisata Therapeutics, Inc.
• ENROLLING BY INVITATIONPHASE3NCT06671418
  Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction
  Erasmus Medical Center
• RECRUITINGNCT05404347
  NGS in Gallbladder Cancer and Response to Treatment
  Banaras Hindu University

See all trials for Carcinoma of gallbladder and extrahepatic biliary tract →